New Delhi [India], January 21 (ANI/PNN): Fermenta Biotech Limited (FBL) today announced that it has signed a Definitive Agreement with Aurigene Pharmaceutical Services Limited (APSL), a stepdown subsidiary of Dr Reddy's Laboratories Limited (DRL).

New Delhi [India], January 12 (ANI): Antiviral drug Molnupiravir is not included in the National treatment task force for COVID-19, said Director General, Indian Council of Medical Research (ICMR) Balram Bhargava on Wednesday.

New Delhi [India], January 11 (ANI): Molnupiravir, an oral antiviral drug used in the treatment of COVID-19 should not be administered to the younger population as it adversely affects their reproductive system, said Dr NK Arora, Chairman of COVID-19 Working Group of National Technical Advisory Group on Immunisation (NTAGI).

New Delhi [India], January 5 (ANI): Indian Council of Medical Research (ICMR) head Dr. Balram Bhargava on Wednesday stated that the oral anti-viral drug Molnupiravir capsules are not included in the national task force treatment for COVID-19 as it has side effects.

A one-of-a-kind anti-viral COVID-19 pill, Molnupiravir was cleared in India for treating adults with coronavirus. Additionally, it is also approved for people “who have a high risk of progression of the diseases”. Read to know all about the COVID-19 pill. What is Molnupiravir? How does it work? Molnupiravir (MK-4482, EIDD-2801), initially made for treating influenza […]

Mumbai (Maharashtra) [India], December 28 (ANI): Drug Controller General of India (DCGI) on Tuesday granted Emergency Use Authorisation (EUA) to Cipla for the launch of Molnupiravir in the country for COVID-19 treatment.

Hyderabad (Telangana) [India], December 28 (ANI/PNN): Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.

New Delhi Dec 28 PTI Drug major Cipla on Tuesday said it has received emergency use authorisation EUA permission from the Drug Controller General of India DCGI to launch antiviral drug Molnupiravir in the country to treat mild-to-moderate COVID-19 The Mumbai-based firm said it plans to launch Molnupiravir under the brand name Cipmolnu This launch is yet another step in our endeavour to enable access to all treatments in COVID care We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients Cipla MD and Global CEO Umang Vohra said in a statement Earlier during the year Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme MSD to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries LMICs The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency MHRA for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease Molnupiravir inhibits the replication of multiple RNA viruses including SARS-CoV-2 Cipla said it will soon make Cipmolnu 200mg capsules available at all leading pharmacies and COVID treatment centers across the country The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India it added PTI MSS DRR

New Delhi Dec 27 PTI An expert panel of the Central Drugs Standard Control Organisation CDSCO on Monday recommended granting permission to manufacture and market anti-Covid pill Molnupiravir for restricted emergency use for the treatment of COVID-19 patients in the country official sources said The emergency use of the drug will be for adult COVID-19 patients with SpO2 93 percent and who have a high risk of progression of the disease including hospitalisation or death subject to certain conditions they added Dr Reddys Laboratories in consortium with Cipla Mylan Torrent Emcure and Sun Pharma had presented their proposal for approval of Molnupiravir 200mg capsules for approval in the emergency situation along with various supporting documents including clinical data in the country Considering the emergency and unmet medical need in COVID-19 the Committee recommended for grant of permission to manufacture and market Molnupiravir for restricted use under emergency situation in the country for treatment of adult patients with COVID 19 with SpO2 93 percent and who have high risk of progression of the disease including hospitalisation or death subject to certain conditions a source said As per conditions the drug should be sold in retail only under the prescription of medical specialists According to the conditions the drug is not authorised for use in patients less than 18 years and for initiation of treatment in patients requiring immediate hospitalisation due to COVID-19 at that stage However if it was initiated before hospitalisation due to COVID 19 it may be continued the sources said The pill is not authorsied for use for longer than five consecutive days and for pre-exposure or post-exposure prophylaxis for prevention of COVID-19 for pregnant women they said The US Food and Drug Administration recently authorised Mercks Molnupiravir for treatment of mild-to-moderate COVID-19 cases in adults who are at risk for severe disease Before that in November Britain granted conditional authorisation to Mercks coronavirus antiviral the first pill shown to successfully treat coronavirus The pill is intended to be taken twice a day for five days by people at home with mild to moderate COVID-19 In a clinical trial of high-risk people during the early course of illness Mercks drug was shown to reduce hospitalisations and deaths by around 30 percent PTI PLB AQS AQS

New Delhi [India], December 27 (ANI): After reviewing all applications and data on antiviral pills, the Subject expert committee (SEC) a body under India's drug regulator will be meeting today for antiviral pill Molnupiravir recommendations, sources told to ANI.